InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | 2026-05-11 | Hanson Kristopher | General Counsel | Sale | 13.9K | $30.13 | $419K | 162.3K | View ↗ | |
| 2026-05-11 | 2026-05-11 | Kroeger Christopher A. | Director & Chief Executive Officer | Sale | 14.0K | $30.11 | $421K | 1.51M | View ↗ | |
| 2026-05-08 | 2026-05-11 | Kroeger Christopher A. | Director & Chief Executive Officer | Sale | 34.4K | $27.69 | $953K | 1.53M | View ↗ | |
| 2026-05-07 | 2026-05-11 | Kroeger Christopher A. | Director & Chief Executive Officer | Sale | 20.1K | $28.65 | $576K | 1.56M | View ↗ | |
| 2026-05-07 | 2026-05-11 | Foff Erin Pennock | Chief Medical Officer | Sale | 4,438 | $28.54 | $127K | 346.1K | View ↗ |
No annual data found.
MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
MapLight Therapeutics to Participate in Upcoming Investor Conferences
This MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of April
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results